Grant ID DP150087
Awarded On November 19, 2014
Title Pre-IND Development of OxaliTex
Program Academic Research
Award Mechanism Bridging the Gap: Early Translational Research Awards
Institution/Organization The University of Texas at Austin
Principal Investigator/Program Director Jonathan Sessler
Cancer Sites Ovary
Contracted Amount $1,464,504
Lay Summary

Platinum chemotherapy is the go-to therapy for many cancers including NSCLC and ovarian cancer. Unfortunately, cisplatin and the two other FDA-approved platinum drugs oxaliplatin and carboplatin are highly non-selective, meaning they attack healthy tissue in addition to the tumor. This dose-limiting problem is compounded when the patient has developed platinum resistant cancer. Platinum resistance is considered responsible in large measure for the low (5-20%) 5-year survival rates seen in these cancers.

The PI’s research group at The Univ. of Texas at Austin (UTA) has specialized in developing cancer-specific anticancer agents (called texaphyrins) for the last 20 years. An recent collaborati...

Read More